NetScientific PLC Vortex BioSciences granted critical patent (0312Z)
15 Setembro 2015 - 3:01AM
UK Regulatory
TIDMNSCI
RNS Number : 0312Z
NetScientific PLC
15 September 2015
NetScientific plc
Vortex BioSciences granted critical patent for its Liquid Biopsy
technology
London, UK - 15 September 2015 - NetScientific plc
("NetScientific" or the "Group", AIM: NSCI), the transatlantic
biomedical and healthcare technology group, announces that one of
its key portfolio companies, Vortex BioSciences Inc., has been
granted a critical patent on its core technology in the US.
Vortex BioSciences is a cancer diagnostic instrument company
providing liquid biopsy solutions for isolating, detecting and
harvesting circulating tumour cells ('CTC's) from cancer patients'
blood sample for use in downstream clinical applications such as
monitoring disease progression and drug treatment
effectiveness.
The granted patent, licensed exclusively to Vortex from UCLA,
was also recently issued in China and Australia and covers its core
technology of inertial microfluidics and its application to the
separation and collection of cells of interest including CTCs. This
US patent covers the unique microfluidic chip design and
performance of the Vortex assay, enabling flow of samples such as
blood and collection of cells of interest via microfluidic channels
and vortices. The patent also covers collection of CTCs from the
chip for downstream analysis such as counting, cytology and DNA
sequencing.
Dr Michael Boyce-Jacino, Head of US Operations at NetScientific:
"This key patent provides strong protection of our novel and
powerful new platform technology for cell separation. Alongside our
three previously issued patents, this US patent strengthens our
global market position as we prepare to beta launch our VTX-1
product in the US later this year."
Notes to Editors
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment.
For more information, please visit the website at
www.netscientific.net.
About Vortex BioSciences Inc.
Vortex BioSciences is a cancer diagnostic instrument company
developing the Vortex VTX-1 bench top instrument, which runs a
simplified, high-speed blood test for a wide range of metastatic
cancers. The instrument harvests live CTCs from patient blood
samples for use in downstream clinical applications such as
monitoring disease progression and drug treatment effectiveness.
The Company will sell laboratory instruments along with single use
cartridges for each blood sample. For more information, please
visit the website at www.vortexbiosciences.com.
Contact Details
NetScientific Tel: +44 (0)20 3514
François Martelet, 1800
CEO
Peter Thoms, CFO
Investec Tel: +44 (0)20 7597
Gary Clarence / Daniel 4000
Adams
Instinctif Partners Tel: +44 (0)20 7457
Melanie Toyne-Sewell / 2020 Email: netscientific@instinctif.com
Jayne Crook
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAFNLFLASEAF
(END) Dow Jones Newswires
September 15, 2015 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024